Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2004

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Xcellerated T Cells

Trial Locations (18)

20817

RECRUITING

Center for Cancer & Blood Disorders, Bethesda

21231

RECRUITING

Johns Hopkins University, Baltimore

29605

RECRUITING

Cancer Centers of the Carolinas, Greenville

30342

RECRUITING

Atlanta Cancer Care, Roswell

43210

RECRUITING

Ohio State University, Columbus

63110

RECRUITING

Washington University, St Louis

77030

RECRUITING

MD Anderson Cancer Center, Houston

80218

RECRUITING

Rocky Mountain Cancer Centers, Denver

90033

NOT_YET_RECRUITING

University of Southern California, Los Angeles

92093

RECRUITING

University of California, San Diego, San Diego

92123

RECRUITING

Sharp Memorial Hospital, San Diego

94143

RECRUITING

University of California, San Francisco, San Francisco

94904

RECRUITING

California Cancer Care, Greenbrae

97239

RECRUITING

Oregon Health Sciences University, Portland

98104

RECRUITING

Swedish Cancer Institute, Seattle

98111

RECRUITING

Virginia Mason, Seattle

02115

RECRUITING

Dana-Farber Cancer Institute, Boston

08903

RECRUITING

Cancer Institute of New Jersey, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Xcyte Therapies

INDUSTRY

NCT00081783 - Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients | Biotech Hunter | Biotech Hunter